$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications
Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.